Results 121 to 130 of about 50,700 (273)

Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection. [PDF]

open access: yes, 2014
Background: The number of patients who have undergone intravitreal injections has increased enormously in recent years, but a consensus is still lacking on prophylaxis for endophthalmitis.
Arias Barquet, Lluís   +4 more
core   +2 more sources

Corneal transplantation: Restoring sight to the blind

open access: yesActa Ophthalmologica, EarlyView.
Abstract Corneal blindness is one of the leading causes of vision loss worldwide. Transplantation of the cornea can restore vision and make blind patients see again. Corneal transplant surgery has undergone major evolution in recent decades with the advent of minimally invasive lamellar surgical approaches such as DMEK and DALK.
Claus Cursiefen
wiley   +1 more source

Intravitreal bevacizumab versus ranibizumab: Effects on the vessels of the fellow non-treated eye

open access: yesJournal of Current Ophthalmology, 2019
Purpose: To evaluate the effects of anti-vascular endothelial growth factors (anti-VEGF) on the vessels of the non-treated eyes following intravitreal injections.
Mohammadreza Peyman   +4 more
doaj   +1 more source

Visual Responses in Mice Lacking Critical Components of All Known Retinal Phototransduction Cascades [PDF]

open access: yes, 2010
The mammalian visual system relies upon light detection by outer-retinal rod/cone photoreceptors and melanopsin-expressing retinal ganglion cells. Gnat1(-/-); Cnga3(-/-); Opn4(-/-) mice lack critical elements of each of these photoreceptive mechanisms ...
Allen, AE   +4 more
core  

Technique of intravitreal injection [PDF]

open access: yesAustralian and New Zealand Journal of Ophthalmology, 1993
N, Morlet   +3 more
openaire   +2 more sources

Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To provide insights into the effectiveness and safety of faricimab for treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD). Methods A retrospective cohort study using a prospectively‐designed registry. Treatment‐naïve eyes with nAMD in Australia starting treatment with faricimab between Jan 2023–Sep 2024 ...
Mark Gillies   +8 more
wiley   +1 more source

Prognostic Factors in Patients With Submacular Haemorrhage Complicating Age‐Related Macular Degeneration: A Post Hoc Analysis of the STAR Study

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To investigate prognostic factors of recent submacular haemorrhage (SMH) complicating neovascular age‐related macular degeneration (nAMD) treated with surgery or pneumatic displacement combined with intravitreal injection of anti‐vascular endothelial growth factor.
Pierre‐Henry Gabrielle   +8 more
wiley   +1 more source

Viral Vector-based Improvement of Optic Nerve Regeneration: Characterization of Individual Axons\u27 Growth Patterns and Synaptogenesis in a Visual Target [PDF]

open access: yes, 2015
Lack of axon growth ability in the central nervous system poses a major barrier to achieving functional connectivity after injury. Thus, a non-transgenic regenerative approach to reinnervating targets has important implications in clinical and research ...
Blackmore, Murray G.   +3 more
core   +1 more source

Stage‐Associated Microglial Subpopulations and Dynamics in Vascular Pathogenesis of Oxygen‐Induced Retinopathy

open access: yesCell Proliferation, EarlyView.
In the oxygen‐induced retinopathy (OIR) mouse model, two distinct microglial subpopulations play opposing roles: highly glycolytic microglia (HGM) promote neovascular formation via Pkm2, while Mrc1/CD206‐positive phagocytosis‐associated microglia (PAM) facilitate its regression.
Yuan Ma   +20 more
wiley   +1 more source

Health, hope and worry: A qualitative study of people with diabetes' experiences with anti‐VEGF treatment

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims Diabetic macular edema (DME) is a leading cause of vision loss among individuals with diabetes. While anti‐VEGF therapy is a widely used and effective treatment, limited research has explored participants' lived experiences throughout the treatment process.
J. K. Leksell   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy